The Wichita Community Clinical Oncology Program (WCCOP), established and funded by the National Cancer Institute in 1983, continued in 1987, 1990, 1995, 2000 and 2005, is a city-wide cooperative program of the major community hospitals, the majority of Wichita's oncologists (19) and five medical oncologists from Lawrence, Kansas. During the past four years, the WCCOP averaged 300 credits per year on treatment protocols. Additionally, the WCCOP has achieved the goal of expanding cancer control trial accrual to exceed treatment accrual with an average of 456 cancer control credits per year over the past four years. The WCCOP plans to continue an annual accrual of 350 credits on treatment protocols and 400 new credits on cancer control protocols using six research bases: the Southwest Oncology Group, North Central Cancer Treatment Group, Eastern Cooperative Group, M.D. Anderson Cancer Center, National Surgical Adjuvant Breast and Bowel Project, University of Rochester Cancer Center, and the Gynecologic Oncology Group as well as the Cancer Trials Support Unit.
The specific aims of the WCCOP are: (1) to stimulate quality medical care through participation in treatment protocols for cancer patients in Wichita, south-central, southwest and northeast Kansas, a patient population that would otherwise be unserved because its geographical location is remote from comprehensive cancer centers;(2) to increase accrual of patients on adult NCI treatment and cancer prevention and control protocols and thus reduce the time necessary to answer critical questions and at the same time speed the transfer of the latest research findings to the community level;(3) to continue to assure quality and timely data collection while also continually implementing measures to protect clinical trial participant safety;(4) to continue to facilitate the involvement of underserved Kansas minority and rural populations in treatment and cancer prevention and control research. With a track record as a successful CCOP for 26 years, and over 5,000 new cancer patients each year, the WCCOP has the necessary expertise and commitment to continue successful therapeutic treatment and cancer prevention and control research efforts. '7 '-

Public Health Relevance

In 2009, about 562,340 Americans, including over 5,000 Kansans, are expected to die of cancer. Clinical trials translate basic scientific research results into better ways to prevent, diagnose, and/or treat cancer. Increasing participation in clinical trials will provide the critical answers being asked much faster. The Wichita CCOP has a proven history of high accrual to cancer clinical trials and therefore has, and wishes to continue to contribute to the reduction of cancer-related co-morbidities and deaths currently experienced.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035431-29
Application #
8330211
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
Whitman, Cynthia B
Project Start
1983-09-15
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
29
Fiscal Year
2012
Total Cost
$2,077,111
Indirect Cost
$319,708
Name
Via Christi Regional Medical Center
Department
Type
DUNS #
056577646
City
Wichita
State
KS
Country
United States
Zip Code
67214
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Coutre, Steven E; Othus, Megan; Powell, Bayard et al. (2014) Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol 165:497-503
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Advani, Anjali S; McDonough, Shannon; Copelan, Edward et al. (2014) SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 167:233-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70

Showing the most recent 10 out of 255 publications